Lisa Rivero

Senior Vice President, Sr Media Strategist, Reputation & Risk Management Practice @Syneos Health

At Syneos, I provide media strategy and issues management for leading biotech and pharma clients. My core responsibilities are to provide strategic media counsel around clinical milestones, executive media training, product launches, crisis management and product communications. I also lead the patient engagement program for Zogenix/UCB for storytelling around FINTEPLA, which treats rare epilepsy syndromes (Dravet and LGS). In March 2023, I led the strategy and media engagement for Acadia\'s FDA approval of DAYBUE™ (trofinetide) and is the first and only drug approved for the treatment of Rett syndrome. In December 2022, I drove the media strategy and execution for Entrada Therapeutics\' collaboration deal with Vertex to treat Myotonic Dystrophy (DM1), as well as led the media strategy on the approval for Ferring\'s drug Adstiladrin®, a novel adenovirus vector-based gene therapy, for the treatment of invasive bladder cancer (NMIBC). In 2020 and 2021, I lead the media strategy for 3 rare disease product launches; Alnylam\'s OXLUMO™ (lumasiran) for primary hyperoxaluria type 1 (PH1), Eiger\'s Zokinvy™ (lonafarnib) for Hutchinson-Gilford Progeria Syndrome, and Albireo\'s Bylvay™ (odevixibat), the first treatment for Progressive Familial Intrahepatic Cholestasis (PFIC). In the last four years, I have worked with a variety of clients including Alnylam, GSK Vaccines, Boston Scientific, Zogenix (now UCB), Entrada, Medtronic, Acadia, Seres, Tmunity, Albireo, and Eiger. I also have long-standing relationships with biotech and business media, as well as consumer outlets. Recent story placements include the TODAY Show, Wall Street Journal, Reuters, Forbes, Huffington Post, MM+M, Endpoints and STAT. I also lead several executive visibility programs securing keynotes and panels at Fast Company Innovation Festival, the Atlantic, Forbes Healthcare Summit, Aspen Health, STAT Summit, Financial Times Global Pharmaceutical and Biotech Conference, On Helix and Xconomy\'s Biotech Week.